Literature DB >> 28522776

A case of rivaroxaban-associated acute tubulointerstitial nephritis.

R C Monahan1, M M Suttorp, B A Th F Gabreëls.   

Abstract

Rivaroxaban is a direct oral anticoagulant that is prescribed for the prevention and treatment of thromboembolisms. Rivaroxaban is cleared renally and a common side effect (1-10%) is renal impairment of unknown pathophysiology. We are the first to describe a case of biopsy-proven acute tubulointerstitial nephritis, most likely caused by rivaroxaban.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28522776

Source DB:  PubMed          Journal:  Neth J Med        ISSN： 0300-2977            Impact factor:   1.422


  4 in total

1.  Dabigatran-Induced Nephropathy and Gastrointestinal Bleeding and Its Successful Treatment with Idarucizumab: A Case Report.

Authors:  Francesca Marchesini; Andrea Ossato; Alberto Zendrini; Federica Arginelli; Teresa Zuppini; Nicola Realdon; Massimo Zamperini; Roberto Tessari
Journal:  Hosp Pharm       Date:  2021-05-22

2.  Dabigatran-Induced Acute Interstitial Nephritis: An Important Complication of Newer Oral Anticoagulation Agents.

Authors:  Swapnil Patel; Mohammad A Hossain; Firas Ajam; Mayurkumar Patel; Mihir Nakrani; Jasmine Patel; Alsadiq Alhillan; Mohamed Hammoda; Anas Alrefaee; Michael Levitt; Arif Asif
Journal:  J Clin Med Res       Date:  2018-09-10

3.  Rivaroxaban-Induced Acute Interstitial Nephritis: A Case Report.

Authors:  Fahad Zafar; Arshad Muhammad Iqbal; Ateeq Mubarik; Melanie Rojas; Salman Muddassir
Journal:  Am J Case Rep       Date:  2019-11-21

4.  Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use.

Authors:  Zhen-Ling Deng; Wen-Ling Yang; Xin-Yue Zhao; Zi-Yong Tang; Dan-Xia Zheng; Yue Wang
Journal:  Ren Fail       Date:  2022-01-27       Impact factor: 3.222
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.